Actively Recruiting
Pharmacologic Augmentation of TMS for Depression With D-serine
Led by Mclean Hospital · Updated on 2025-10-31
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.
CONDITIONS
Official Title
Pharmacologic Augmentation of TMS for Depression With D-serine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of major depressive disorder (MDD)
- English-speaking
- Adults aged 18 to 80 years
- Ability to swallow capsules
You will not qualify if you...
- Presence of implanted metal or devices
- Current or previous history of seizures
- Active substance use that may affect seizure threshold
- Pre-existing kidney disease
- Known allergy to D-serine
- Use of medications with known drug interactions
- Children
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McLean Hospital
Belmont, Massachusetts, United States, 02478
Actively Recruiting
Research Team
J
Joshua C Brown, MD, PhD
CONTACT
J
Julia Tom, BS, MSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here